Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.16B |
| 2 |
Bank of America
BAC
|
+$855M |
| 3 |
Comcast
CMCSA
|
+$620M |
| 4 |
Amazon
AMZN
|
+$505M |
| 5 |
Micron Technology
MU
|
+$486M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$441M |
| 2 |
Palo Alto Networks
PANW
|
+$300M |
| 3 |
Verizon
VZ
|
+$286M |
| 4 |
Fidelity National Information Services
FIS
|
+$285M |
| 5 |
Stanley Black & Decker
SWK
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Financials | 6.16% |
| 3 | Industrials | 5.09% |
| 4 | Consumer Discretionary | 4.89% |
| 5 | Healthcare | 4.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
PUT
National Beverage
FIZZ
$2.93B
| $6.4M | ﹤0.01% |
131,400
+71,800
| +120% | +$3.68M |
|
2052
PUT
British American Tobacco
BTI
$123B
| $6.4M | ﹤0.01% |
95,500
+44,700
| +88% | +$2.91M |
|
2053
CALL
Dominion Energy
D
$60.5B
| $6.4M | ﹤0.01% |
78,900
+32,500
| +70% | +$2.63M |
|
|
CBAY
2054
DELISTED
Cymabay Therapeutics
CBAY
| $6.39M | ﹤0.01% |
694,252
+54,225
| +8% | +$463K |
|
2055
PUT
Clorox
CLX
$12.8B
| $6.38M | ﹤0.01% |
42,900
-7,000
| -14% | -$952K |
|
2056
PUT
Williams-Sonoma
WSM
$28.4B
| $6.38M | ﹤0.01% |
246,600
-38,400
| -13% | -$979K |
|
|
AMAG
2057
DELISTED
AMAG Pharmaceuticals
AMAG
| $6.38M | ﹤0.01% |
+481,129
| New | +$7.25M |
|
2058
CALL
Darden Restaurants
DRI
$25.6B
| $6.37M | ﹤0.01% |
66,300
-2,600
| -4% | -$220K |
|
2059
Westlake Corp
WLK
$10.2B
| $6.36M | ﹤0.01% |
59,734
-835,154
| -93% | -$77.4M |
|
2060
Selective Insurance
SIGI
$5.62B
| $6.35M | ﹤0.01% |
108,181
+62,777
| +138% | +$3.63M |
|
2061
PUT
TAL Education Group
TAL
$6.46B
| $6.35M | ﹤0.01% |
213,700
-137,300
| -39% | -$4.18M |
|
2062
PUT
TotalEnergies
TTE
$196B
| $6.33M | ﹤0.01% |
10,491,063
+2,373,845
| +29% | +$1.42M |
|
2063
PUT
Diamondback Energy
FANG
$56.7B
| $6.33M | ﹤0.01% |
50,100
+5,700
| +13% | +$618K |
|
2064
PUT
Zimmer Biomet
ZBH
$19.2B
| $6.32M | ﹤0.01% |
53,972
+15,038
| +39% | +$1.7M |
|
|
FRAN
2065
DELISTED
Francesca's Holdings Corporation
FRAN
| $6.31M | ﹤0.01% |
71,946
+54,716
| +318% | +$4.6M |
|
2066
Maximus
MMS
$2.89B
| $6.31M | ﹤0.01% |
88,136
-43,432
| -33% | -$2.92M |
|
2067
CALL
GSK
GSK
$99.2B
| $6.31M | ﹤0.01% |
142,240
+43,280
| +44% | +$2M |
|
2068
Strategy Inc
MSTR
$36.6B
| $6.3M | ﹤0.01% |
480,120
-84,470
| -15% | -$1.13M |
|
|
2069
CALL
Clorox
CLX
$12.8B
| $6.29M | ﹤0.01% |
42,300
+17,900
| +73% | +$2.44M |
|
2070
PUT
Tyson Foods
TSN
$20.5B
| $6.29M | ﹤0.01% |
77,600
-11,600
| -13% | -$888K |
|
2071
Outfront Media
OUT
$5.33B
| $6.29M | ﹤0.01% |
275,494
-85,412
| -24% | -$2M |
|
2072
WisdomTree Europe Hedged Equity Fund
HEDJ
$1.88B
| $6.29M | ﹤0.01% |
197,394
+44,212
| +29% | +$1.44M |
|
2073
iShares Core S&P US Value ETF
IUSV
$28B
| $6.29M | ﹤0.01% |
+113,424
| New | +$6.1M |
|
2074
PUT
Cigna
CI
$74.7B
| $6.28M | ﹤0.01% |
30,900
+6,200
| +25% | +$1.23M |
|
2075
iShares MSCI Kokusai Fund
TOK
$258M
| $6.27M | ﹤0.01% |
96,976
+86,545
| +830% | +$5.54M |
|
Similar funds
Ken Griffin's Q4 2017 Portfolio in Review
As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.
- Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
- Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
- Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
- Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
- Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
- Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.